Stocks · News reference
Analyst Calls Curium's $8 Billion Lantheus Buyout An 'Excellent Outcome' For Shareholders
CapVest-backed Curium agrees to acquire Lantheus for up to $8B, expanding its global footprint in nuclear medicine.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Lantheus Holdings, Inc. (LNTH)
Filed: 2026-09-21 AccNo: 0001193125-26-396654 Size: 159 KB Item 8.01: Other Events
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
Curium announced FDA approval of BEXLUTRY, a radioligand therapy for treating somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The approval marks Curium's first radioligand therapy and represents expansion into oncology therapeutics. The company also announced acquisitions of Abscint SA and a definitive merger agreement with Lantheus to create a global radiopharmaceutical leader.
FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics
Lantheus receives FDA approval for PET imaging agent used to evaluate adults for Alzheimer's disease by identifying tau pathology.